LinkedIn Image Expert Review Modules 2017 Year in Review: Highlights for Lung Cancer

Expert Review Modules 2017 Year in Review: Highlights for Lung Cancer

View Activity

Activity Features

CME-Certified

Downloadable Slides

Expert Discussion

Opinion Poll

prIME Points™

Activity Overview

This Expert Review features internationally-renowned thought leaders discussing practice-changing data released in 2017 regarding the use of targeted therapy and immunotherapy, as well as molecular testing, in non-small cell lung cancer (NSCLC).

Featured Discussants

  • Tony Mok, MD, FRCP, The Chinese University of Hong Kong, Hong Kong, China
  • Roy S. Herbst, MD, PhD, Yale Cancer Center, New Haven, Connecticut, United States

Featured Topic

Module 1: Advances in Targeted Therapy

Featured Discussants

  • David Planchard, MD, PhD, Gustave Roussy, Villejuif, France
  • Geoffrey R. Oxnard, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

Module 2: Novel Approaches to Molecular Testing

Featured Discussants

  • Julie Brahmer, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
  • Shirish Gadgeel, MD, University of Michigan, Ann Arbor, Michigan, United States

Featured Topic

Module 3: Immunotherapy for Early-Stage and Locally Advanced NSCLC

Featured Discussants

  • Roy S. Herbst, MD, PhD, Yale Cancer Center, New Haven, Connecticut, United States
  • Heather Wakelee, MD, Stanford University, Stanford, California, United States

Featured Topic

Module 4: Immunotherapy for Metastatic NSCLC

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

ACCME-commendation-full-color

prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and Disclosure Information

Support

This educational activity is supported by grants from AstraZeneca and Merck.